Biogen’s Longer-Lasting MS Drug Meets Goals in Late Trial

Published: Thursday, January 24th 2013

(Bloomberg) - Biogen Idec Inc. (BIIB) said its longer- lasting injectable multiple sclerosis drug, peginterferon beta-1a, helped reduce patients’ risk of relapse by 36 percent when given every two weeks, meeting the goals of a late-stage study.

Read more.

Comment(s)

Your comments are valuable to us. Thank you.

5 Rules for Speculating in Biotech

Biogen Sinks as ALS Drug Fails to Show Efficacy in Trial

Biogen Races to FDA with Positive PhIII Data for Hemophilia B Drug

Biogen MS Pill Soars Onstage with Impressive First-Week Script Numbers

Biogen Idec Shares Surge on Positive Multiple Sclerosis Drug Data